benzbromarone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiarrhythmics | 318 | 3562-84-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M04AB03 | MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS ANTIGOUT PREPARATIONS Preparations increasing uric acid excretion |
| CHEBI has role | CHEBI:35841 | uricosuric agent |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D006074 | Gout Suppressants |
| MeSH PA | D014528 | Uricosuric Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperuricemia | indication | 35885006 | DOID:1920 |
| Gout | indication | 90560007 | DOID:13189 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.91 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Solute carrier family 22 member 12 | Transporter | INHIBITOR | IC50 | 7.59 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Adenosine receptor A3 | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 5.98 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 14 | Kinase | IC50 | 5.91 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 5.71 | DRUG MATRIX | |||||
| Multidrug resistance-associated protein 1 | Transporter | Ki | 6.72 | CHEMBL | |||||
| Aldo-keto reductase family 1 member C1 | Enzyme | IC50 | 7.32 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.94 | DRUG MATRIX | |||||
| Envelope glycoprotein gp160 | Unclassified | IC50 | 4.89 | CHEMBL | |||||
| M1-family alanyl aminopeptidase | Unclassified | IC50 | 4.20 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4POG0RL69O | UNII |
| N0000166974 | NUI |
| D01056 | KEGG_DRUG |
| C0005035 | UMLSCUI |
| CHEBI:3023 | CHEBI |
| R75 | PDB_CHEM_ID |
| CHEMBL388590 | ChEMBL_ID |
| DB12319 | DRUGBANK_ID |
| D001553 | MESH_DESCRIPTOR_UI |
| 2333 | PUBCHEM_CID |
| 1427 | INN_ID |
| 1385 | RXNORM |
| 005311 | NDDF |
| 698025001 | SNOMEDCT_US |
| 703372005 | SNOMEDCT_US |
Pharmaceutical products:
None